600594.SH
Guizhou Yibai Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 3.25
+0.31%Oct 30, 2026, 09:54 UTC
Yibai Pharmaceutical reported third-quarter 2026 revenue of RMB 301 million, down 33.73% year over year, and a net loss of RMB 70.9127 million; for the first nine months, revenue was RMB 990 million, down 31.57%, with a net loss of RMB 151 million and an adjusted net loss of RMB 163 million.
Source:Aug 20, 2026, 10:27 UTC
Yibai Pharmaceutical announced its first-half 2026 results: revenue of 689 million yuan, down 30.58% year-on-year, and net loss attributable to shareholders widened to 80.34 million yuan from 19.90 million yuan a year earlier.
Source:Jul 31, 2026, 10:07 UTC
Yibai Pharmaceutical received a Notice of Administrative Penalty from the Guizhou Provincial Drug Administration for failing to comply with Good Manufacturing Practice for drugs, and is proposed to be fined 700,000 yuan.
Source:Jul 2, 2026, 10:56 UTC
Yibai Pharmaceutical elected Dou Qiling as chairman and appointed several senior executives at its board meeting on July 2, 2026.
Source: